UPDATE: H.C. Wainwright Reiterates Buy On Seattle Genetics, Raises Target To $140 As Firm Notes 'Remarkable HER2CLIMB topline positions Seattle Genetics as a strong player in breast cancer space'
Benzinga_Newsdesk